Mark A. Lewis, MD, discusses recent data from the COMMIT trial investing first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.
Novel Antibody-Drug Conjugate Shows Potential in Solid Tumor Treatment
MRG004A, a novel antibody-drug conjugate, elicited antitumor activity and had manageable toxicities when used in heavily pretreated patients with multiple tumor types with high tissue factor.
Read More
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Listen
Adding Nivolumab to Neoadjuvant Chemotherapy Spurs More Evaluation in Pancreatic Cancer
Modified FOLFIRINOX with nivolumab in the neoadjuvant setting was associated with favorable rates of R0 resection in patients with borderline resectable pancreatic cancer.
Unpacking the Latest Research in Gastrointestinal Cancers
In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.
Longer Follow-up Confirms Durability of Zanidatamab in Pretreated HER2+ BTC
Zanidatamab therapy led to confirmed responses, disease control, and favorable overall survival in pretreated HER2+ biliary tract cancer in an update of the HERIZON-BTC-01 trial.
Perioperative Chemotherapy Prolongs OS in Esophageal Cancer
Perioperative chemotherapy with improved OS vs neoadjuvant chemoradiation in resectable esophageal cancer.